Soiken Holdings Inc. (JP:2385)
:2385
Top Page
Soiken Holdings Inc.
(2385)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥235.00
▼(-0.42% Downside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by mixed fundamentals: a very strong, debt-free balance sheet and improved FY2025 cash flow are offset by recent losses and ongoing revenue contraction. Technicals are a key drag, with the price below major moving averages and negative MACD. Valuation is neutral-to-supportive, helped by a modest dividend yield.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure gives durable financial flexibility: it eliminates interest burden, preserves liquidity to fund operations or R&D, supports resilience through downturns, and enables optionality for opportunistic M&A or strategic investments without raising leverage.
Negative Factors
Multi-year revenue contraction
Persistent top-line decline across several years signals structural demand or market-share challenges. Ongoing revenue contraction erodes scale, limits operating leverage, reduces R&D payoff, and makes it harder to restore sustainable profitability even with strong margins or a clean balance sheet.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure gives durable financial flexibility: it eliminates interest burden, preserves liquidity to fund operations or R&D, supports resilience through downturns, and enables optionality for opportunistic M&A or strategic investments without raising leverage.
Read all positive factors
Soiken Holdings Inc. (2385) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.59B
Dividend Yield2.08%
Average Volume (3M)187.76K
Price to Earnings (P/E)19.7
Beta (1Y)0.96
Revenue Growth-10.24%
EPS GrowthN/A
CountryJP
Employees90
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,158,200
10 Day Avg. Volume461,280
30 Day Avg. Volume187,763
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.73
Price to Sales (P/S)0.91
P/FCF Ratio8.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Soiken Holdings Inc. Business Overview & Revenue Model
Company Description
Soiken Holdings Inc. engages in the development of biomarkers in Japan. The company is involved in the development and sale of cosmetics and dietary supplements; licensing and development of biomarker technology; provision of marketing research an...
Soiken Holdings Inc. Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
78
Positive
Cash Flow
55
Neutral
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.85B | 5.16B | 8.08B | 9.35B | 8.94B |
| Gross Profit | 2.41B | 2.48B | 3.72B | 4.26B | 4.11B |
| EBITDA | -201.93M | -583.21M | 750.07M | 1.23B | 948.13M |
| Net Income | -210.70M | -662.20M | 451.85M | 809.71M | 562.06M |
Balance Sheet | |||||
| Total Assets | 6.81B | 6.96B | 8.24B | 8.49B | 7.15B |
| Cash, Cash Equivalents and Short-Term Investments | 5.26B | 4.79B | 5.95B | 6.22B | 4.26B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 775.16M | 708.58M | 1.07B | 1.64B | 915.00M |
| Stockholders Equity | 6.02B | 6.23B | 6.97B | 6.65B | 6.04B |
Cash Flow | |||||
| Free Cash Flow | 521.19M | -895.42M | -141.08M | 2.09B | -131.65M |
| Operating Cash Flow | 557.96M | -880.82M | -101.55M | 2.14B | -107.44M |
| Investing Cash Flow | -389.41M | -14.29M | 160.37M | -244.58M | -24.85M |
| Financing Cash Flow | -214.00K | -260.71M | -130.21M | -129.94M | -131.25M |
Soiken Holdings Inc. Technical Analysis
Positive
236.00
Price Trends
250.18
Positive
245.29
Positive
212.06
Positive
Market Momentum
0.30
Negative
58.81
Neutral
91.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2385, the sentiment is Positive. The current price of 236 is below the 20-day moving average (MA) of 243.60, below the 50-day MA of 250.18, and above the 200-day MA of 212.06, indicating a bullish trend. The MACD of 0.30 indicates Negative momentum. The RSI at 58.81 is Neutral, neither overbought nor oversold. The STOCH value of 91.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2385.
Soiken Holdings Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥4.54B | -828.32 | ― | ― | -0.77% | -288.43% | |
53 Neutral | ¥6.59B | 19.71 | ― | 2.08% | -10.24% | ― | |
52 Neutral | ¥5.83B | -2.65 | ― | 5.44% | -15.42% | -879.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥7.09B | -5.04 | ― | ― | ― | ― | |
46 Neutral | ¥8.32B | -5.66 | ― | ― | 5.44% | -2.17% | |
43 Neutral | ¥6.32B | -6.68 | ― | ― | ― | ― |
* Healthcare Sector Average
JP:2385
Soiken Holdings Inc.
252.00
126.73
101.17%
JP:2183
Linical Co., Ltd.
258.00
-19.43
-7.00%
JP:2342
Trans Genic Inc.
269.00
92.00
51.98%
JP:2370
MEDINET Co., Ltd.
30.00
-1.00
-3.23%
JP:4891
TMS Co., Ltd.
139.00
-11.00
-7.33%
JP:206A
PRISM BioLab Co. LTD
192.00
-41.00
-17.60%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.